Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.

Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received ≥4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action. The cytotoxic and potential immunomodulatory properties of belamaf have led to novel combination studies with other anticancer therapies. Here, we describe the rationale and design of DREAMM-5, an ongoing Phase I/II platform study evaluating the safety and efficacy of belamaf combined with novel agents, including GSK3174998 (OX40 agonist), feladilimab (an ICOS; GSK3359609), nirogacestat (a gamma-secretase inhibitor; PF-03084014) and dostarlimab (a PD-1 blocker) versus belamaf monotherapy for patients with relapsed/refractory multiple myeloma. Clinical trial registration: NCT04126200 (ClinicalTrials.gov).

[1]  S. Trudel,et al.  DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) , 2020 .

[2]  A. Nooka,et al.  DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM) , 2020 .

[3]  M. Dimopoulos,et al.  DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) , 2020 .

[4]  S. Lonial,et al.  Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study , 2020, Blood Cancer Journal.

[5]  M. Bi,et al.  Abstract 2220: Non-clinical tumor models reveal broad combination potential of ICOS agonist antibodies , 2020 .

[6]  A. Jakubowiak,et al.  Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study , 2020, Ophthalmology and Therapy.

[7]  Y. Tai,et al.  BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma , 2020, Cancers.

[8]  Yu Chen,et al.  Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice , 2020, Frontiers in Immunology.

[9]  P. Richardson,et al.  DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM). , 2020 .

[10]  T. Myklebust,et al.  Incidence and survival of multiple myeloma: a population‐based study of 10 524 patients diagnosed 1982–2017 , 2020, British journal of haematology.

[11]  A. Chari,et al.  B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches , 2020, Leukemia.

[12]  S. Lonial,et al.  Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. , 2019, The Lancet. Oncology.

[13]  M. Boccadoro,et al.  Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies , 2019, Cancers.

[14]  J. A. Krueger,et al.  Synergistic Activity of Belantamab Mafodotin (anti-BCMA immuno-conjugate) with PF-03084014 (gamma-secretase inhibitor) in Bcma-Expressing Cancer Cell Lines , 2019, Blood.

[15]  D. Siegel,et al.  Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE‐023 study , 2019, British journal of haematology.

[16]  I. Melero,et al.  Dendritic cells in cancer immunology and immunotherapy , 2019, Nature Reviews Immunology.

[17]  Herman Goossens,et al.  Adaptive platform trials: definition, design, conduct and reporting considerations , 2019, Nature Reviews Drug Discovery.

[18]  Jason J. Z. Liao,et al.  Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. , 2019, The Lancet. Haematology.

[19]  Yingqi Hua,et al.  Immunogenic cell death in cancer therapy: Present and emerging inducers , 2019, Journal of cellular and molecular medicine.

[20]  R. Sullivan,et al.  Preliminary safety, efficacy, and pharmacokinetic/pharmacodynamic characterization from GARNET, a phase I/II clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-h and MSS endometrial cancer , 2019, Gynecologic Oncology.

[21]  O. Kepp,et al.  PF558 THE ANTI-BCMA ANTIBODY-DRUG CONJUGATE GSK2857916 DRIVES IMMUNOGENIC CELL DEATH AND IMMUNE-MEDIATED ANTI-TUMOR RESPONSES, AND IN COMBINATION WITH AN OX40 AGONIST POTENTIATES IN VIVO ACTIVITY , 2019, HemaSphere.

[22]  Karl Broich,et al.  Master protocols in clinical trials: a universal Swiss Army knife? , 2019, The Lancet. Oncology.

[23]  M. Parmar,et al.  Mind the gap? The platform trial as a working environment , 2019, Trials.

[24]  V. Bragulat,et al.  Phase I/II, open-label, 2-arm study to evaluate safety, tolerability, and clinical activity of GSK2857916 in combination with 2 standard-of-care (SoC) regimens in relapsed/refractory multiple myeloma: (DREAMM 6). , 2019, Journal of Clinical Oncology.

[25]  S. Trudel,et al.  Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study , 2019, Blood Cancer Journal.

[26]  R. Vij,et al.  Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy , 2019, Leukemia.

[27]  S. Trudel,et al.  Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. , 2018, The Lancet. Oncology.

[28]  M. Dimopoulos,et al.  Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting , 2018, Blood Cancer Journal.

[29]  D. Olive,et al.  Preclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  P. Richardson,et al.  How I treat the young patient with multiple myeloma. , 2018, Blood.

[31]  M. Dimopoulos,et al.  Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trial , 2018, Cancer.

[32]  K. Anderson,et al.  Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy , 2018, Front. Immunol..

[33]  A. Hoos,et al.  The promise and challenges of immune agonist antibody development in cancer , 2018, Nature Reviews Drug Discovery.

[34]  A. Gural,et al.  Daratumumab resistance is frequent in advanced‐stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis , 2018, European journal of haematology.

[35]  P. Richardson,et al.  CD38 antibodies in multiple myeloma: back to the future. , 2018, Blood.

[36]  H. Lokhorst,et al.  Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update , 2017, Drugs.

[37]  A. Lesokhin,et al.  Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. , 2017, Blood.

[38]  J. Woodcock,et al.  Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. , 2017, The New England journal of medicine.

[39]  T. Golde,et al.  γ‐Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct , 2017, EMBO molecular medicine.

[40]  P. Sonneveld,et al.  How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients? , 2017, Critical reviews in oncology/hematology.

[41]  P. Meltzer,et al.  Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  J. Wolchok,et al.  Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity , 2017, Nature Communications.

[43]  T. Spektor,et al.  Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients , 2016, Haematologica.

[44]  S. Lonial,et al.  New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma , 2016, Clinical Cancer Research.

[45]  K. Yong,et al.  Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma , 2016, British journal of haematology.

[46]  A. Palumbo,et al.  Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.

[47]  H. Goldschmidt,et al.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.

[48]  M. Delforge,et al.  Multiple myeloma: patient outcomes in real‐world practice , 2016, British journal of haematology.

[49]  Sandra A Mitchell,et al.  Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[50]  U. Mellqvist,et al.  Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group , 2016, Leukemia.

[51]  S. Berry,et al.  Efficiencies of platform clinical trials: A vision of the future , 2016, Clinical trials.

[52]  M. Mcnamara,et al.  OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal , 2015, Front. Oncol..

[53]  Anthony O'Hagan,et al.  Robust meta‐analytic‐predictive priors in clinical trials with historical control information , 2014, Biometrics.

[54]  A. Jimeno,et al.  A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014 , 2014, Clinical Cancer Research.

[55]  N. Munshi,et al.  Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. , 2014, Blood.

[56]  T. Luetkens,et al.  Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma , 2014, Leukemia.

[57]  B. Fox,et al.  OX40 is a potent immune-stimulating target in late-stage cancer patients. , 2013, Cancer research.

[58]  S. Vincent Rajkumar,et al.  Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients , 2013, Leukemia.

[59]  J. Crowley,et al.  Serum B‐cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival , 2012, British journal of haematology.

[60]  H. Goldschmidt,et al.  Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study , 2012, Leukemia.

[61]  D. Munn,et al.  Blockade of Programmed Death-1 Pathway Rescues the Effector Function of Tumor-Infiltrating T Cells and Enhances the Antitumor Efficacy of Lentivector Immunization , 2010, The Journal of Immunology.

[62]  Yuan Ji,et al.  A modified toxicity probability interval method for dose-finding trials. , 2010, Clinical trials.

[63]  M. Caligiuri,et al.  The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. , 2010, Blood.

[64]  S. Rosenberg,et al.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. , 2009, Blood.

[65]  T. So,et al.  The significance of OX40 and OX40L to T‐cell biology and immune disease , 2009, Immunological reviews.

[66]  M. Dimopoulos,et al.  Treatment of relapsed/refractory multiple myeloma. , 2009, Seminars in hematology.

[67]  Michael Branson,et al.  Critical aspects of the Bayesian approach to phase I cancer trials , 2008, Statistics in medicine.

[68]  Yoshimasa Tanaka,et al.  Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer , 2007, Proceedings of the National Academy of Sciences.

[69]  Wei Zhu,et al.  An agonist human ICOS monoclonal antibody that induces T cell activation and inhibits proliferation of a myeloma cell line. , 2004, Hybridoma and hybridomics.

[70]  M. Nishimura,et al.  B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression , 2004, Clinical Cancer Research.

[71]  R. Bram,et al.  BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells , 2004, The Journal of experimental medicine.

[72]  T. Horan,et al.  Potent activity of soluble B7RP‐1‐Fc in therapy of murine tumors in syngeneic hosts , 2003, International journal of cancer.

[73]  R. Schiffman,et al.  Reliability and validity of the Ocular Surface Disease Index. , 2000, Archives of ophthalmology.

[74]  A. Barclay,et al.  Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes‐‐a molecule related to nerve growth factor receptor. , 1990, The EMBO journal.

[75]  S. Mboup,et al.  Minerva Access is the Institutional Repository of The University of Melbourne , 2021 .

[76]  R. Herbst,et al.  Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. , 2016, JAMA oncology.

[77]  S. Lonial,et al.  New Targets and New Agents in High-Risk Multiple Myeloma. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[78]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.